sgp130-Fc therapy to help recovery after traumatic brain injury
Development of Novel sgp130-Fc Bioconjugates for TBI
A new drug designed to block harmful IL-6–related inflammation and help people recover better after moderate-to-severe traumatic brain injury.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Gryphon Bio, INC. NIH-funded |
| Lab location | 1 site (South San Francisco, United States) |
| Project ID | NIH-11386364 on NIH RePORTER |
What this research studies
This project is developing a drug based on sgp130-Fc that aims to block IL-6 “trans-signaling,” a type of inflammation linked to worse recovery after TBI. The team will create bioconjugates that improve the drug's stability and ability to reach the brain, then test them in laboratory and animal experiments. Their work builds on clinical findings showing IL-6 and related proteins in blood and CSF are tied to long-term outcomes, including cognition and mood. The long-term goal is to advance a candidate toward human trials during the sub-acute and rehabilitation phases after injury.
Who could benefit from this research
Good fit: People who had moderate-to-severe traumatic brain injury and are in the sub-acute or chronic recovery period (weeks to months after injury) would be the likely candidates for future trials.
Not a fit: Those with mild TBI, injuries far outside the intended treatment window, or medical conditions that prevent trial participation are less likely to benefit from this program.
Why it matters
Potential benefit: If successful, this approach could lower chronic inflammation after TBI and improve cognitive recovery and mood outcomes.
How similar studies have performed: Targeting IL-6 trans-signaling with sgp130 is a relatively new approach with supportive biomarker and preclinical signals but no established human treatment yet.
Where this research is happening
South San Francisco, United States
- Gryphon Bio, INC. — South San Francisco, United States (Active)
Researchers
- Principal investigator: Haskins, William E — Gryphon Bio, INC.
- Study coordinator: Haskins, William E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.